Wealth Enhancement Advisory Services’s Rhythm Pharmaceuticals RYTM Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$204K	Buy	+1,885	New	+$170K	﹤0.01%	3570

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wealth Enhancement Advisory Services's RYTM Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 1,885 shares worth $204K. The stake represents ﹤0.01% of the portfolio and ranks #3570 among its holdings.

304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Wealth Enhancement Advisory Services held 1,885 shares of Rhythm Pharmaceuticals worth $204K as of Q2 2026.
Rhythm Pharmaceuticals was a new Wealth Enhancement Advisory Services position in Q2 2026.
Rhythm Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3570 holding.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.